Shortcomings in the technical documentation of mesh implants intended to treat pelvic organ prolapse used in the Netherlands After a detailed assessment of the technical documentation of 9 different mesh implants intended to treat pelvic organ prolapse used in NL (2018) RIVM concludes that the safety and performance of these products were not properly substantiated.
Use of e-health increases but not always effective 2021 saw an increase in the use of e-health in every part of the healthcare industry in comparison with 2019. There were several reasons for this, including the coronavirus pandemic.
New WHO Collaborating Centre hosted by RIVM combines laboratory preparedness and biorisk RIVM has been designated WHO Collaborating Centre for Laboratory Preparedness and Response for High Threat Pathogens and Biorisk by the World Health Organization (WHO).
The 13-week scan now available for pregnant women Since 1 September, pregnant women in the Netherlands can have an early ultrasound scan to detect physical abnormalities in their unborn child: the 13-week scan.
Launch of the European project RISK-HUNT3R The new Horizon 2020 project RISK-HUNT3R: RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rs was launched on 1 June.
More reports of adverse effects of implants in 2019 In 2019, the Dutch reporting centre for adverse effects of medical implants (MEBI) received 397 reports of suspected adverse effects. The reports concerned 462 implants.
Mesh implants intended to treat pelvic organ prolapse Synthetic mesh are used to treat patients with pelvic organ prolapse.
Towards a sustainable, healthy future for everyone: EU project INHERIT offers policy solutions Today, on 10 December a policy toolkit will be presented at the final conference of the European four-year research project INHERIT.
Summary International Expert Meeting on breast implant-associated lymphoma On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).